Solu-Cortef
Adrenal Insufficiency
Vastra Gotaland RegionPhase 3Active
BB
68/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 55/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Adrenal Insufficiency cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
TETRACOSACTIDE University of Virginia | Phase 3 | BB |
Same molecule, other indications
Solu-Cortef is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →